Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: Alpelisib|DRUG: Fulvestrant
Sponsor: Novartis Pharmaceuticals